Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Colon

Internal Medicine Charlotte, NC Medical Doctor

NPI 1447406079 CMS profile 155894

10635 Park Rd Ste I, Charlotte, NC 28210

Open in the dashboard

General payments

$5,265

300 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Colon of Charlotte, NC is reported in the CMS Open Payments database as having received $5,265 across 300 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,045 48
2024 General $838 45
2023 General $856 47
2022 General $475 27
2021 General $356 23
2020 General $285 19
2019 General $1,409 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Colon
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to David Colon were reported at $1,045. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year David Colon Internal Medicine median Middle half National median
2019 $1,409 $159 $48–$570 $163
2020 $285 $119 $33–$402 $114
2021 $356 $135 $37–$521 $132
2022 $475 $141 $42–$496 $149
2023 $856 $149 $45–$519 $160
2024 $838 $154 $47–$537 $164
2025 $1,045 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $578 33 payments
  2. AbbVie, Inc. $555 26 payments
  3. Novo Nordisk Inc $535 36 payments
  4. AstraZeneca Pharmaceuticals LP $471 28 payments
  5. Pfizer Inc. $394 20 payments
  6. GlaxoSmithKline, LLC. $290 16 payments
  7. Lilly USA, LLC $271 18 payments
  8. Janssen Pharmaceuticals, Inc $227 13 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $207 11 payments
  10. Merck Sharp & Dohme Corporation $143 9 payments
  11. Other $1,595 90 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,250 299 payments
  2. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $369 16 payments
  2. Repatha $348 18 payments
  3. QULIPTA $341 13 payments
  4. FARXIGA $301 17 payments
  5. Ozempic $283 20 payments
  6. AIMOVIG $211 11 payments
  7. XARELTO $202 12 payments
  8. Otezla $197 11 payments
  9. RYBELSUS $194 14 payments
  10. EVENITY $179 12 payments
  11. Other $5,149 301 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 129 drugs

Part D claims

7,896

Median for Internal Medicine: 777

Drug cost

$661,088

Median for Internal Medicine: $73,373

Branded share of claims

20.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 122 $142,295
Jardiance Empagliflozin Brand 47 $57,944
Eliquis Apixaban Brand 46 $44,899
Januvia Sitagliptin Phosphate Brand 25 $39,159
Myrbetriq Mirabegron Brand 49 $29,483
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $27,411
Linzess Linaclotide Brand 33 $25,463
Farxiga Dapagliflozin Propanediol Brand 15 $24,032
Tradjenta Linagliptin Brand 29 $23,710
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 101 $22,052

The 10 drugs with the highest cost, of 129 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$104,453

Medicare's payments for the services billed

Medicare patients

292

Average age 75

Services billed

3,078

159 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Ischemic heart disease 33%
Diabetes 31%
Depression 29%
Chronic kidney disease 23%
Atrial fibrillation 18%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $96
$96 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $80
$80 15 —
XARELTO
  • Janssen Pharmaceuticals, Inc $63
$63 15 —
Wegovy
  • Novo Nordisk Inc $58
$58 — —
QULIPTA
  • AbbVie, Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

300 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record